On Jun. 29, 2023, the Centers for Disease Control and Prevention (CDC) endorsed the CDC Advisory Committee on Immunization Practicesﾒ (ACIP) recommendations for use of new Respiratory Syncytial Virus (RSV) vaccines from GSK and Pfizer for people ages 60 years and older, using shared clinical decision-making. This means these individuals may receive a single dose of the vaccine based on discussions with their healthcare provider about whether RSV vaccination is right for them.